SAN MARINO, Calif., June 19 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer. Rexin-GTM is the world's first targeted injectable gene therapy vector to be approved for use in clinical trials in the USA and abroad. When injected intravenously, Rexin-GTM seeks out and destroys metastatic cancer, without the systemic toxicity generally associated with chemotherapy.
*(LOGO: Send2Press.com/mediadesk/logo-epeius_72dpi.jpg)
Rexin-GTM recently gained Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials in Rochester MN.
In a statement to the press, Ms. Dana Dornsife, President of the Lazarex Cancer Foundation said: "We are pleased to provide Epeius Biotechnologies Corporation the funds needed to expedite the development of such promising genetic medicines, which -- by improving both the survival and the quality of life -- provide cancer patients with more quality time."
More information: http://www.epeiusbiotech.com
This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com
Epeius Biotechnologies CorporationCONTACT: Clinical Trials, Dr. Erlinda M. Gordon, Medical Director, orMedia, Dr. Frederick L. Hall, President and CEO, both of EpeiusBiotechnologies Corporation, +1-626-441-6695, or fax, +1-626-441-6692,info@epeiusbiotech.com
Web site: http://www.epeiusbiotech.com//
